Tiucă Robert Aurelian, Tiucă Oana Mirela, Pașcanu Ionela Maria
Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, 540142 Targu Mures, Romania.
Department of Endocrinology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, 540142 Targu Mures, Romania.
Biomedicines. 2023 Apr 2;11(4):1075. doi: 10.3390/biomedicines11041075.
Thyroid cancer is the most common endocrine malignancy, with an increasing trend in the past decades. It has a variety of different histological subtypes, the most frequent one being differentiated thyroid cancer, which refers to papillary carcinoma, the most common histological type, followed by follicular carcinoma. Associations between genetic polymorphisms and thyroid cancer have been investigated over the years and are an intriguing topic for the scientific world. To date, the results of associations of single nucleotide polymorphisms, the most common genetic variations in the genome, with thyroid cancer have been inconsistent, but many promising results could potentially influence future research toward developing new targeted therapies and new prognostic biomarkers, thus consolidating a more personalized management for these patients. This review focuses on emphasizing the existing literature data regarding genetic polymorphisms investigated for their potential association with differentiated thyroid cancer and highlights the opportunity of using genetic variations as biomarkers of diagnosis and prognosis for thyroid cancer patients.
甲状腺癌是最常见的内分泌系统恶性肿瘤，在过去几十年中呈上升趋势。它有多种不同的组织学亚型，最常见的是分化型甲状腺癌，其中包括最常见的组织学类型乳头状癌，其次是滤泡状癌。多年来，人们一直在研究基因多态性与甲状腺癌之间的关联，这是科学界一个引人入胜的话题。迄今为止，作为基因组中最常见的基因变异，单核苷酸多态性与甲状腺癌的关联研究结果并不一致，但许多有前景的结果可能会影响未来开发新的靶向治疗和新的预后生物标志物的研究，从而巩固对这些患者更个性化的管理。这篇综述着重强调了现有文献中关于基因多态性与分化型甲状腺癌潜在关联的研究数据，并突出了将基因变异用作甲状腺癌患者诊断和预后生物标志物的机会。
